HK Pharmaceuticals is seeking to partner with pharmaceutical and biotechnology companies to understand and eliminate undesired side effects which could prohibit a drug from reaching its full commercial potential – either due to withdrawal from the market or failure in late stage clinical trials. HK Pharmaceuticals’ CCMS™ technology can be incorporated early in the drug development process, leading to a better understanding of structure-function relationships and mechanism of action and indicating that certain drug candidates should be abandoned early in the process before large investments have been made. 

HK Pharmaceuticals is also seeking partnerships for new drug target discovery and drug development, in which novel protein targets, including membrane proteins, will be discovered and characterized using HK Pharmaceuticals’ CCMS™ technology. HK Pharmaceuticals has initiated internal projects in diabetes and leukemia, and the Company’s technology will be utilized in other disease areas in collaboration with corporate partners.